Kyrgyzstan

Kyrgyzstan

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
2.55 (2.13 - 2.91) 2019 Modelled IHME
2.65 (2.22 - 2.98) 2018 Modelled IHME
2.74 (2.27 - 3.12) 2017 Modelled IHME
2.79 (2.33 - 3.18) 2016 Modelled IHME
2.84 (2.35 - 3.32) 2015 Modelled IHME
2.92 (2.40 - 3.40) 2014 Modelled IHME
3.01 (2.47 - 3.51) 2013 Modelled IHME
3.1 (2.52 - 3.64) 2012 Modelled IHME
3.19 (2.59 - 3.76) 2011 Modelled IHME
3.27 (2.64 - 3.87) 2010 Modelled IHME
3.34 (2.71 - 3.92) 2009 Modelled IHME
3.41 (2.81 - 3.96) 2008 Modelled IHME
3.48 (2.89 - 4) 2007 Modelled IHME
3.54 (2.98 - 4.05) 2006 Modelled IHME
3.6 (3.05 - 4.15) 2005 Modelled IHME
3.66 (3.11 - 4.18) 2004 Modelled IHME
3.72 (3.15 - 4.26) 2003 Modelled IHME
3.78 (3.21 - 4.32) 2002 Modelled IHME
3.84 (3.24 - 4.42) 2001 Modelled IHME
3.9 (3.28 - 4.55) 2000 Modelled IHME
3.98 (3.34 - 4.63) 1999 Modelled IHME
4.08 (3.40 - 4.73) 1998 Modelled IHME
4.18 (3.45 - 4.83) 1997 Modelled IHME
4.26 (3.46 - 4.91) 1996 Modelled IHME
4.28 (3.45 - 4.95) 1995 Modelled IHME
4.28 (3.45 - 4.93) 1994 Modelled IHME
4.26 (3.43 - 4.93) 1993 Modelled IHME
4.22 (3.43 - 4.90) 1992 Modelled IHME
4.17 (3.39 - 4.86) 1991 Modelled IHME
4.08 (3.32 - 4.80) 1990 Modelled IHME
3.39 (0.34 - 19.81) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.64 (0.50 - 0.81) 2019 Modelled IHME
0.71 (0.54 - 0.92) 2018 Modelled IHME
0.74 (0.53 - 0.96) 2017 Modelled IHME
0.71 (0.52 - 0.90) 2016 Modelled IHME
0.66 (0.50 - 0.84) 2015 Modelled IHME
0.63 (0.48 - 0.79) 2014 Modelled IHME
0.6 (0.45 - 0.75) 2013 Modelled IHME
0.57 (0.42 - 0.72) 2012 Modelled IHME
0.54 (0.40 - 0.69) 2011 Modelled IHME
0.52 (0.38 - 0.67) 2010 Modelled IHME
0.5 (0.37 - 0.63) 2009 Modelled IHME
0.48 (0.36 - 0.61) 2008 Modelled IHME
0.46 (0.35 - 0.58) 2007 Modelled IHME
0.45 (0.34 - 0.56) 2006 Modelled IHME
0.45 (0.34 - 0.56) 2005 Modelled IHME
0.56 (0.42 - 0.70) 2004 Modelled IHME
0.85 (0.64 - 1.07) 2003 Modelled IHME
1.24 (0.93 - 1.57) 2002 Modelled IHME
1.65 (1.22 - 2.09) 2001 Modelled IHME
2 (1.46 - 2.54) 2000 Modelled IHME
2.33 (1.73 - 2.93) 1999 Modelled IHME
2.7 (2.03 - 3.36) 1998 Modelled IHME
3.04 (2.27 - 3.78) 1997 Modelled IHME
3.29 (2.46 - 4.10) 1996 Modelled IHME
3.39 (2.52 - 4.26) 1995 Modelled IHME
3.39 (2.54 - 4.20) 1994 Modelled IHME
3.37 (2.55 - 4.16) 1993 Modelled IHME
3.32 (2.50 - 4.08) 1992 Modelled IHME
3.22 (2.44 - 4) 1991 Modelled IHME
3.06 (2.33 - 3.86) 1990 Modelled IHME
0.5 (0.05 - 3.76) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
23 (17 - 30) 2019 Modelled IHME
22 (17 - 30) 2018 Modelled IHME
22 (17 - 30) 2017 Modelled IHME
22 (17 - 30) 2016 Modelled IHME
22 (17 - 30) 2015 Modelled IHME
23 (17 - 30) 2014 Modelled IHME
23 (17 - 30) 2013 Modelled IHME
23 (17 - 31) 2012 Modelled IHME
23 (18 - 31) 2011 Modelled IHME
23 (18 - 31) 2010 Modelled IHME
23 (18 - 31) 2009 Modelled IHME
24 (18 - 31) 2008 Modelled IHME
24 (18 - 32) 2007 Modelled IHME
24 (18 - 31) 2006 Modelled IHME
24 (18 - 31) 2005 Modelled IHME
24 (18 - 31) 2004 Modelled IHME
24 (17 - 31) 2003 Modelled IHME
23 (17 - 31) 2002 Modelled IHME
23 (17 - 31) 2001 Modelled IHME
23 (17 - 31) 2000 Modelled IHME
23 (17 - 31) 1999 Modelled IHME
23 (16 - 31) 1998 Modelled IHME
23 (16 - 31) 1997 Modelled IHME
23 (16 - 31) 1996 Modelled IHME
23 (16 - 31) 1995 Modelled IHME
23 (16 - 30) 1994 Modelled IHME
22 (16 - 30) 1993 Modelled IHME
22 (16 - 30) 1992 Modelled IHME
22 (16 - 30) 1991 Modelled IHME
22 (16 - 30) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
97 2018 Survey/reported WHO/UNICEF
97 2017 Survey/reported WHO/UNICEF
96 2016 Survey/reported WHO/UNICEF
97 2015 Survey/reported WHO/UNICEF
99 2014 Survey/reported WHO/UNICEF
96 2013 Survey/reported WHO/UNICEF
94 2012 Survey/reported WHO/UNICEF
73 2011 Survey/reported WHO/UNICEF
99 2010 Survey/reported WHO/UNICEF
98 2009 Survey/reported WHO/UNICEF
98 2008 Survey/reported WHO/UNICEF
98 2007 Survey/reported WHO/UNICEF
97 2006 Survey/reported WHO/UNICEF
98 2005 Survey/reported WHO/UNICEF
99 2004 Survey/reported WHO/UNICEF
99 2003 Survey/reported WHO/UNICEF
99 2002 Survey/reported WHO/UNICEF
93 2001 Survey/reported WHO/UNICEF
45 2000 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
92 2018 Survey/reported WHO/UNICEF
92 2017 Survey/reported WHO/UNICEF
96 2016 Survey/reported WHO/UNICEF
97 2015 Survey/reported WHO/UNICEF
96 2014 Survey/reported WHO/UNICEF
97 2013 Survey/reported WHO/UNICEF
96 2012 Survey/reported WHO/UNICEF
96 2011 Survey/reported WHO/UNICEF
96 2010 Survey/reported WHO/UNICEF
96 2009 Survey/reported WHO/UNICEF
97 2008 Survey/reported WHO/UNICEF
94 2007 Survey/reported WHO/UNICEF
90 2006 Survey/reported WHO/UNICEF
97 2005 Survey/reported WHO/UNICEF
99 2004 Survey/reported WHO/UNICEF
99 2003 Survey/reported WHO/UNICEF
99 2002 Survey/reported WHO/UNICEF
57 2001 Survey/reported WHO/UNICEF
44 2000 Survey/reported WHO/UNICEF
10 1999 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
246 (166 - 366) 2014 Survey/reported UNDP, 2014; Kyrgyzstan Republican AIDS Centre, 2013
Technical notes
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
1998
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
Yes
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Few (1-10%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
3.69 (2.99 - 4.53) 2019 Modelled IHME
3.69 (3 - 4.52) 2018 Modelled IHME
3.7 (2.99 - 4.55) 2017 Modelled IHME
3.73 (3.05 - 4.56) 2016 Modelled IHME
3.77 (3.06 - 4.64) 2015 Modelled IHME
3.82 (3.10 - 4.67) 2014 Modelled IHME
3.86 (3.15 - 4.71) 2013 Modelled IHME
3.91 (3.18 - 4.80) 2012 Modelled IHME
3.94 (3.20 - 4.81) 2011 Modelled IHME
3.95 (3.20 - 4.85) 2010 Modelled IHME
3.95 (3.20 - 4.84) 2009 Modelled IHME
3.95 (3.19 - 4.86) 2008 Modelled IHME
3.94 (3.17 - 4.85) 2007 Modelled IHME
3.93 (3.17 - 4.87) 2006 Modelled IHME
3.92 (3.14 - 4.88) 2005 Modelled IHME
3.91 (3.14 - 4.83) 2004 Modelled IHME
3.9 (3.15 - 4.81) 2003 Modelled IHME
3.89 (3.14 - 4.78) 2002 Modelled IHME
3.87 (3.11 - 4.76) 2001 Modelled IHME
3.84 (3.08 - 4.72) 2000 Modelled IHME
3.8 (3.05 - 4.66) 1999 Modelled IHME
3.73 (3 - 4.58) 1998 Modelled IHME
3.65 (2.93 - 4.52) 1997 Modelled IHME
3.59 (2.88 - 4.47) 1996 Modelled IHME
3.56 (2.85 - 4.45) 1995 Modelled IHME
3.56 (2.86 - 4.43) 1994 Modelled IHME
3.57 (2.87 - 4.43) 1993 Modelled IHME
3.57 (2.87 - 4.44) 1992 Modelled IHME
3.58 (2.88 - 4.44) 1991 Modelled IHME
3.6 (2.89 - 4.44) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
2.5 (1.60 - 6.70) 2014 Modelled Gower et al, 2014
People who inject drugs (PWID)
Download
Value (%) Year Type Source
43.9 (40.60 - 47.20) 2013 Survey/reported Chokmorova U et al, 2013

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
36 (27 - 45) 2019 Modelled IHME
36 (28 - 45) 2018 Modelled IHME
37 (28 - 45) 2017 Modelled IHME
37 (28 - 45) 2016 Modelled IHME
37 (28 - 45) 2015 Modelled IHME
36 (28 - 44) 2014 Modelled IHME
36 (27 - 44) 2013 Modelled IHME
36 (27 - 44) 2012 Modelled IHME
35 (27 - 44) 2011 Modelled IHME
35 (27 - 44) 2010 Modelled IHME
36 (27 - 44) 2009 Modelled IHME
35 (27 - 44) 2008 Modelled IHME
35 (27 - 44) 2007 Modelled IHME
35 (27 - 44) 2006 Modelled IHME
36 (27 - 44) 2005 Modelled IHME
36 (27 - 44) 2004 Modelled IHME
36 (27 - 44) 2003 Modelled IHME
37 (28 - 45) 2002 Modelled IHME
37 (28 - 45) 2001 Modelled IHME
37 (28 - 45) 2000 Modelled IHME
37 (28 - 45) 1999 Modelled IHME
37 (28 - 46) 1998 Modelled IHME
37 (27 - 46) 1997 Modelled IHME
37 (27 - 46) 1996 Modelled IHME
37 (27 - 46) 1995 Modelled IHME
37 (28 - 46) 1994 Modelled IHME
37 (28 - 46) 1993 Modelled IHME
37 (28 - 46) 1992 Modelled IHME
37 (28 - 46) 1991 Modelled IHME
37 (28 - 46) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (166 - 366) 2014 Survey/reported UNDP, 2014; Kyrgyzstan Republican AIDS Centre, 2013
Technical notes
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
1998
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
Yes
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Few (1-10%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
2.55 (%)
2019
(2.13 - 2.91(%))
IHME
HCV (RNA/cAg+)
3.69 (%)
2019
(2.99 - 4.53(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
404
2019
(292 - 548)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
509
2019
(372 - 675)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.64 (%)
2019, latest modelled
(0.50 - 0.81(%))
IHME

Prevalence PWID

HCV
43.90 (%)
2013, survey/surveillance
(40.60 - 47.20(%))
Chokmorova U et al, 2013

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
97 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

HCV
246
2014
(166 - 366)
UNDP, 2014; Kyrgyzstan Republican AIDS Centre, 2013
Eligible for HBV generic medicines
Eligible for HCV generic medicines